Abstract
BackgroundFrom 2009 Abatacept (ABA) – a new generation biological DMARD was approved in Russia. ABA selectively modulates T-cell activation, which seems to play the key role in the pathogenesys of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have